AOP Health Presents Final Results From Its CONTINUATION-PV Study – up to 7.5 Years Treatment With BESREMi® (Ropeginterferon alfa-2b) of Polycythaemia Vera Patients – at EHA 2022 Annual Meeting
Business Wire India AOP Health announced the final results on Ropeginterferon alfa-2b in patients with Polycythaemia Vera (PV) from its CONTINUATION-PV study in an oral presentation at the prestigious EHA…